** Adaptimmune up 30 percent on news that secondsolid tumour type responds to its cell therapy, boosting hopesfor biotech company's NY-ESO SPEAR T-cells partnered withGlaxoSmithKline
** Adaptimmune reports three partial responses (twoconfirmed and one to be confirmed) and one case of stabledisease in the first four patients dosed in myxoid/round cellliposarcoma trial
** GSK licensed rights to NY-ESO cell therapy in September2017 and
** Adaptimmune founded to exploit cell therapy technologyoriginally developed at Oxford University and firm listed onNasdaq in 2015